Paper Details

  1. Home
  2. Paper Details

Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.

Author: JarzabBarbara, KrajewskaJolanta, OlczykTomasz

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Cabozantinib, a potent inhibitor of MET, VEGFR 2/KDR, RET, and other kinases, demonstrates efficacy in treating medullary thyroid cancer (MTC). In a study, cabozantinib significantly prolonged progression-free survival in both hereditary and sporadic MTC. While overall survival did not differ significantly, a subgroup with RET M918T mutation showed significant improvement. Common side effects include diarrhea, palmar-plantar erythrodysesthesia, weight loss, nausea, fatigue, and hypertension. Cabozantinib is a viable treatment option for MTC patients with RET M918T mutation, showing prolonged overall survival.
Paper Details　
Original Abstract of the Article :
Cabozantinib (XL-184) is a potent inhibitor of MET, VEGFR 2/KDR, RET and other receptor tyrosine kinases, such as KIT, AXL and FLT3. Its efficacy against MTC has been demonstrated in a prospective, randomized, placebo-controlled study (EXAM). Cabozantinib comparing to placebo significantly prolonged...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1586/17512433.2016.1102052

データ提供：米国国立医学図書館（NLM）

Cabozantinib: A New Hope in the Desert of Medullary Thyroid Cancer

Medullary thyroid cancer (MTC), a type of thyroid cancer, can be a tough battle, but researchers are continuously seeking new weapons in the fight. This study investigates the efficacy of cabozantinib, a multi-targeted tyrosine kinase inhibitor, in treating progressive metastatic MTC. Cabozantinib has shown promising results in a randomized controlled trial, significantly prolonging progression-free survival in both hereditary and sporadic MTC. While overall survival didn't show a global difference, the drug demonstrated significant improvement in overall survival for patients with the RET M918T mutation. This finding suggests that cabozantinib could be a valuable treatment option for a specific subset of MTC patients.

Cabozantinib: A Targeted Approach to MTC

The study provides evidence that cabozantinib could be a valuable treatment option for patients with MTC, particularly those with the RET M918T mutation. The drug significantly prolonged progression-free survival and showed significant improvement in overall survival for this specific subgroup. This targeted approach to treatment offers hope for patients who have exhausted other treatment options.

Living with Medullary Thyroid Cancer

Living with MTC can be a challenging journey, but advances in treatment options, like cabozantinib, offer hope for patients. It's crucial to stay informed, discuss treatment options with your doctor, and participate in clinical trials to contribute to finding new and effective therapies. Remember, the fight against cancer is a long journey, but there is strength in knowledge and perseverance.

Dr.Camel's Conclusion

This study offers a glimmer of hope in the desert of MTC research. Cabozantinib's potential to benefit patients with the RET M918T mutation highlights the importance of personalized medicine and targeted therapies in cancer treatment. Further research is needed to explore its full potential and improve outcomes for all MTC patients.

Date :
  1. Date Completed 2016-06-22
  2. Date Revised 2015-11-27
Further Info :

Pubmed ID

26536165

DOI: Digital Object Identifier

10.1586/17512433.2016.1102052

Related Literature

Article Analysis
・Effects of cabozantinib (thyroid cancer)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.